TREACE MEDICAL CONCEPTS INC

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

TMCI$4.78+18.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Year Ended December 31,
	2023	2022	2021
Revenue	$187,118	$141,838	$94,419
Cost of goods sold	35,181	25,532	16,888
Gross profit	151,937	116,306	77,531
Operating expenses
Sales and marketing	140,894	104,567	65,405
Research and development	15,440	13,584	10,204
General and administrative	47,031	32,999	18,432
Total operating expenses	203,365	151,150	94,041
Loss from operations	(51,428)	(34,844)	(16,510)
Interest income	6,726	1,313	17
Interest expense	(5,167)	(4,398)	(4,060)
Debt extinguishment loss	—	(4,483)	—
Other income, net	342	(403)	1
Other non-operating income (expense), net	1,901	(7,971)	(4,042)
Net loss	(49,527)	(42,815)	(20,552)
Convertible preferred stock cumulative and undeclared dividends	—	—	(196)
Net loss attributable to common stockholders	$(49,527)	$(42,815)	$(20,748)
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities	190	(27)	—
Comprehensive loss	$(49,337)	$(42,842)	$(20,748)
Net loss per share attributable to common stockholders, basic and diluted	$(0.81)	$(0.77)	$(0.43)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	60,852,153	55,276,834	48,415,679

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.